Recent 8-K filings for LRMR

• May 14, 2026, 7:02 AM ET other material materiality 0.85 positive item 2.02item 8.01item 9.01

  Larimar plans rolling BLA for nomlabofusp in June 2026; Q1 net loss $29.6M

  Net loss Q1 2026 $29.6M ($0.31/sh) vs Q1 2025 $29.3M ($0.46/sh). Cash $200.4M.

• March 19, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Larimar reports Q4 net loss $62.5M; BLA for nomlabofusp on track for June 2026 submission

  Net loss Q4 2025 $62.5M ($0.73/sh) vs $28.8M ($0.45/sh) in Q4 2024; R&D expenses rose to $59.4M.

• February 27, 2026, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 9.01 ◈ Material Agreements

  Larimar Therapeutics prices 20M share public offering at $5.00 per share; underwriters exercise over-allotment

  Offering of 20,000,000 shares plus 3,000,000 over-allotment shares at $5.00 per share.

• February 24, 2026, 6:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Larimar Therapeutics receives FDA Breakthrough Therapy Designation for nomlabofusp in Friedreich's ataxia

  FDA granted Breakthrough Therapy Designation for nomlabofusp for adults and children with Friedreich's ataxia.

• November 5, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Larimar Therapeutics Q3 2025: Net loss $47.7M, nomlabofusp shows 100% FXN level in OL study

  Net loss for Q3 2025 was $47.7M ($0.61 per share) vs $15.5M in Q3 2024, with R&D expenses up to $44.9M.

• September 29, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Larimar reports positive nomlabofusp data; all 6-month patients reach carrier-level FXN

  10/10 participants at 6 months achieved skin FXN >50% of healthy volunteer median (asymptomatic carrier levels).

• August 14, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 8.01item 9.01

  Larimar Therapeutics reports Q2 2025 net loss $26.2M; BLA for nomlabofusp on track for Q2 2026

  Net loss $26.2M ($0.41/share) vs $21.6M ($0.34) in Q2 2024; R&D expenses $23.4M, up from $19.7M.

• July 31, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01

  Larimar Therapeutics prices $64.4M common stock offering at $3.20 per share

  Offering of 18,750,000 shares of common stock at $3.20; underwriters' over-allotment of 2,812,500 shares exercised in full.

• June 23, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Larimar gets FDA safety database guidance; nomlabofusp BLA submission planned for Q2 2026

  FDA recommends safety database of ≥30 participants with 6-month continuous exposure (≥10 with 1-year), majority on 50 mg dose.

• April 30, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Larimar Q1 net loss $29.3M; FDA open to accelerated approval using skin FXN as surrogate endpoint

  Net loss $29.3M ($0.46 per share) vs $14.7M ($0.27) YoY; R&D spend rose to $26.6M on manufacturing and Phase 3 prep.

• March 24, 2025, 7:59 PM ET regulatory materiality 0.80 positive item 2.02item 8.01item 9.01

  Larimar reports FDA open to FXN as surrogate endpoint; BLA submission on track for end-2025

  FDA considers skin FXN concentration reasonably likely surrogate endpoint for accelerated approval of nomlabofusp in Friedreich's ataxia.

• December 16, 2024, 6:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Larimar reports positive OLE data: FXN up to 30% of healthy in buccal cells at Day 90; BLA filing targeted 2H 2025

  Mean change from baseline of 1.32 pg/μg in buccal cells and 9.28 pg/μg in skin cells at Day 90.

• October 30, 2024, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 8.01item 9.01

  Larimar reports Q3 2024 net loss of $15.5M; cash $203.7M, BLA target 2H 2025

  Net loss of $15.5M ($0.24 per share) vs $9.1M loss ($0.21 per share) in Q3 2023.

• August 7, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 8.01item 9.01

  Larimar Q2 net loss $21.6M; cash $226.1M; OLE interim data Q4; FDA START program

  Net loss $21.6M ($0.34/sh) vs $8.4M loss in Q2 2023; R&D spend $19.7M up from $5.9M on manufacturing.

• May 20, 2024, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  FDA removes partial clinical hold on Larimar's nomlabofusp for Friedreich's Ataxia

  FDA cleared Phase 2 data review; nomlabofusp generally well-tolerated with dose-dependent frataxin increases.

• May 9, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 8.01item 9.01 ◈ Earnings Releases

  Larimar Q1 net loss $14.7M; cash $239M; nomlabofusp Phase 2 positive; OLE dosed; BLA target 2H 2025

  Net loss $14.7M ($0.27/shr) vs $6.5M in Q1 2023; R&D expenses rose to $12.9M on manufacturing and clinical costs.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.55 · Most common event other_material

11 positive 1 negative 21 neutral

source · LRMR on sec.gov